TORRENT PHARMACEUTICALS
|
TORRENT PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 48.94 | 36.79 | 45.92 | 73.97 | 60.55 |
| CEPS(Rs) | 72.82 | 57.67 | 42.52 | 56.42 | 49.61 |
| DPS(Rs) | 28.00 | 22.00 | 48.00 | 35.00 | 32.00 |
| Book NAV/Share(Rs) | 202.57 | 183.13 | 351.75 | 344.90 | 284.99 |
| Tax Rate(%) | 29.58 | 32.59 | 36.60 | 17.98 | 13.64 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.13 | 17.30 | 15.98 | 16.67 | 14.51 |
| EBIT Margin(%) | 16.20 | 13.36 | 9.74 | 12.63 | 10.95 |
| Pre Tax Margin(%) | 14.08 | 11.32 | 8.06 | 10.26 | 7.94 |
| PAT Margin (%) | 9.92 | 7.63 | 5.11 | 8.41 | 6.85 |
| Cash Profit Margin (%) | 14.75 | 11.96 | 9.46 | 12.84 | 11.23 |
| Performance Ratios | |||||
| ROA(%) | 11.43 | 9.20 | 5.92 | 9.20 | 7.50 |
| ROE(%) | 25.38 | 20.50 | 13.18 | 23.49 | 21.47 |
| ROCE(%) | 24.28 | 20.32 | 14.35 | 17.62 | 15.28 |
| Asset Turnover(x) | 1.15 | 1.21 | 1.16 | 1.09 | 1.09 |
| Sales/Fixed Asset(x) | 1.27 | 1.39 | 1.43 | 1.43 | 1.48 |
| Working Capital/Sales(x) | 89.70 | -122.18 | 20.28 | 23.62 | -31.47 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.79 | 0.72 | 0.70 | 0.70 | 0.68 |
| Receivable days | 41.38 | 39.99 | 37.86 | 38.92 | 37.65 |
| Inventory Days | 49.26 | 52.47 | 61.71 | 59.24 | 49.84 |
| Payable days | 279.66 | 243.50 | 306.08 | 383.19 | 381.76 |
| Valuation Parameters | |||||
| PER(x) | 53.15 | 41.79 | 30.45 | 17.18 | 16.28 |
| PCE(x) | 35.72 | 26.66 | 32.88 | 22.52 | 19.87 |
| Price/Book(x) | 12.84 | 8.40 | 7.95 | 7.37 | 6.92 |
| Yield(%) | 1.08 | 1.43 | 1.72 | 1.38 | 1.62 |
| EV/Net Sales(x) | 8.50 | 5.90 | 5.99 | 5.90 | 4.85 |
| EV/Core EBITDA(x) | 26.60 | 19.66 | 19.38 | 18.62 | 16.82 |
| EV/EBIT(x) | 33.68 | 26.03 | 34.40 | 25.13 | 23.54 |
| EV/CE(x) | 8.44 | 4.94 | 4.04 | 3.46 | 2.84 |
| M Cap / Sales | 8.21 | 5.41 | 5.56 | 5.37 | 4.20 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 11.51 | 13.07 | 6.29 | 0.82 | 3.47 |
| Core EBITDA Growth(%) | 18.65 | 9.87 | 3.58 | 10.71 | 12.33 |
| EBIT Growth(%) | 24.08 | 47.24 | -21.19 | 14.78 | 53.68 |
| PAT Growth(%) | 33.02 | 60.22 | -37.92 | 22.17 | 134.86 |
| EPS Growth(%) | 33.02 | -19.88 | -37.92 | 22.17 | 134.88 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.57 | 0.85 | 0.68 | 0.83 | 1.21 |
| Current Ratio(x) | 1.03 | 0.98 | 1.17 | 1.13 | 0.91 |
| Quick Ratio(x) | 0.62 | 0.57 | 0.62 | 0.59 | 0.52 |
| Interest Cover(x) | 7.65 | 6.54 | 5.81 | 5.32 | 3.63 |
| Total Debt/Mcap(x) | 0.04 | 0.10 | 0.08 | 0.11 | 0.18 |
Compare Financial Ratios of peers of TORRENT PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| TORRENT PHARMACEUTICALS | ₹113,756.5 Cr | 4.3% | 5% | 59.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,544.0 Cr | 2.8% | -2.7% | 50.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹164,865.0 Cr | 3.5% | 5.4% | 67.6% | Stock Analytics | |
| CIPLA | ₹123,920.0 Cr | 2.9% | -1.2% | 25.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,224.0 Cr | 2.1% | -3.9% | 6.9% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,832.3 Cr | 3.3% | -2% | 53.5% | Stock Analytics | |
TORRENT PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TORRENT PHARMACEUTICALS | 4.3% |
5% |
59.6% |
| SENSEX | 1.1% |
1.1% |
22.2% |
You may also like the below Video Courses
